Antitumor Peptide Derived From A Complementarity Determining Region of a Humanized Monoclonal Antibody to NAP12B Transporter
AssigneeRecepta Biopharma S.A.
InventorLuiz Rodolpho Raja Gabaglia Travassos
Life of this patent
Estimating the term…
Abstract
Described herein is novel isolated or synthetic peptides derived from a complementarity determining region hypervariable domain amino acid sequence of a humanized monoclonal antibody to NaPi2B transporter, as well as derivatives thereof, and a pharmaceutical composition and a method for inhibiting tumor growth or treating a tumor or cancer treating using the antitumor peptides and derivatives thereof.
Claims17
A method of inhibiting tumor growth comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition, wherein the composition comprises an antitumor peptide selected from the group consisting of SEQ ID NOS:
- 3, 8, 9, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, and 33, and a pharmaceutically acceptable carrier or diluent.
The method of claim 11, wherein the cancer is one selected from the group consisting of melanoma, colon cancer, lung cancer, renal cancer, breast cancer, brain cancer, head and neck cancer, gastric and intestinal cancer, prostate cancer, liver cancer and glioblastoma.
The method of claim 13, wherein the cancer is one selected from the group consisting of melanoma, colon cancer, lung cancer, renal cancer, breast cancer, brain cancer, head and neck cancer, gastric and intestinal cancer, prostate cancer, liver cancer and glioblastoma.
The method of claim 15, wherein the cancer is one selected from the group consisting of melanoma, colon cancer, lung cancer, renal cancer, breast cancer, brain cancer, head and neck cancer, gastric and intestinal cancer, prostate cancer, liver cancer and glioblastoma.
The method of claim 17, wherein the cancer is one selected from the group consisting of melanoma, colon cancer, lung cancer, renal cancer, breast cancer, brain cancer, head and neck cancer, gastric and intestinal cancer, prostate cancer, liver cancer and glioblastoma.
Dependencies are inferred from the claim text.